Bay Island Cell, a biotech firm founded by Fan Xiaohu, has secured 140 million RMB in Series A funding led by Songhe Capital. The company is developing a non-gene-edited universal CAR-T technology platform, aiming to produce CAR-T therapies that are more affordable and scalable, akin to standard biologics. Fan Xiaohu, formerly of Legend Biotech, aims to overcome the high cost and long production times associated with current CAR-T treatments, presenting early human trial data at the American Society of Clinical Oncology (ASCO) annual meeting. AI
IMPACT This development in cell therapy could lead to more accessible treatments for various diseases, potentially impacting the broader healthcare landscape.
RANK_REASON Significant funding round for a biotech company developing a novel therapeutic approach. [lever_c_demoted from significant: ic=1 ai=0.4]
- American Society of Clinical Oncology
- Bay Island Cell
- Fan Xiaohu
- Legend Biotech
- Oriental Fortune Capital
- Songhe Capital
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
